Active Stocks
Mon Apr 15 2024 15:59:36
  1. Tata Steel share price
  2. 160.90 -1.59%
  1. ITC share price
  2. 425.90 -0.98%
  1. State Bank Of India share price
  2. 757.75 -1.17%
  1. ICICI Bank share price
  2. 1,078.80 -2.30%
  1. NTPC share price
  2. 361.35 -0.08%
Business News/ Markets / Stock Markets/  JB Pharma share price rises more than 4% post Q3 results: Scales 52-week highs as net profit grows 26% year-on-year
BackBack

JB Pharma share price rises more than 4% post Q3 results: Scales 52-week highs as net profit grows 26% year-on-year

Stock Market today: J.B. Chemicals & Pharmaceuticals (JB Pharma) share price was trading with gains of more than 4% on Wednesday. The share price had risen more than 12% during morning trades to scale 52-week highs. During Q3, the company's' net profit grew at a strong pace of 26% y-o-y.

J.B. Chemicals share price gains more than 4% post Q3 results: Scales 52-week highs (REUTERS)Premium
J.B. Chemicals share price gains more than 4% post Q3 results: Scales 52-week highs (REUTERS)

J.B. Chemicals & Pharmaceuticals Limited (JB Pharma) share price was trading with gains of more than 4% on Wednesday. the share price had gained more than 12%  during the morning trades to scale 52 week highs post storing Q3 earnings performance reported by the company on Tuesday post market hours. The net profit for J. B Chemicals had registered a strong 26% y-o-y growth to 134 crores.

While JB Pharma (J.B Chemicals) recorded revenue of 845 crores in third quarter of FY24 registering growth of 7% from 793 crores in Q3 FY23. 

However it was the strong improvement in operating performance that lifted the earnings. Operating EBITDA* (Earnings before Interest Depreciation and Taxes) for JB Pharma grew by 22% to 235 crores in Q3 FY24 as compared to 193 crores in Q3 FY23.  The gross margins at 67.1% and operating margins 27.8% improved significantly from 62.3% and 22% respectively in the year ago quarter. Profit after Taxes registered strong growth of 26% to 134 crores in Q3 FY24 versus 106 crores in Q3 FY23.

Also read- LIC stock hits new life-time high, outshines CY23 performance in just 27 sessions

Nikhil Chopra, CEO and Wholetime Director, JB Pharma (J.B. Chemicals and Pharmaceuticals) attributed the margin improvement to four factors. The Business mix improved  with rise in Chronic portfolio contributions, however JB Pharma is also seeing rise in CDMO (Contract Development and manufacturing) revenues. Further the efficiency programs being undertaken by the company are yielding results. The company also has cut down on lower margin South African Business that is helping improvement in margins too.

JB Pharma domestic business revenue at 462 crores marked a YoY growth of 14%) in Q3 FY24. 

Chronic business continued to perform well while the acute business witnessed recovery despite muted season said J.B. Chemicals.

New launches in acute and probiotic business of JB Pharma have seen strong performance. In the Probiotics, JB Pharma (J.B.Chemicals) brand Sporlac is Inching towards 100 crore mark. 

Our order book for the CDMO business is looking good for forthcoming quarters, said Chopra.

As earnings for JB Pharma (J.B. Chemicals) saw a strong growth in Q3, it is confident of achieving 10% topline growth during FY24 with Ebitda growing 20% and operating margins expected to come at 27%. JB Pharma's Chopra expects that in two years time JB Pharma will be growing at 12-14%, with Chronic segment contributions at 52%. Ebitda margins for JB Pharma are expected to sustain 26-28% mark driving earnings growth.

Also Read- Lupin, Federal Bank and more: Axis Securities lists 7 top mid and small-cap picks for February

JB Pharma (J.B.Chemicals) also is progressing to grow its ophthalmology segment, post marketing agreement for Novartis brands completed in December.  

The ophthalmology segment holds great promise as we expect this market to grow in mid-teens and consistently outperform IPM growth, said Chopra.

Analysts at BNP Paribas post Ophthalmic segment foray by JB Pharma had said that  Novartis brands build a road to future growth.

Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before taking any investment decisions

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

ABOUT THE AUTHOR
Ujjval Jauhari
Ujjval Jauhari is a deputy editor at Mint, with over a decade of experience in newspapers and digital news platforms. He is skilled in storytelling, reporting, analysing and writing about stocks, investment ideas, markets, corporates and more. He is based in New Delhi.
Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
More Less
Published: 07 Feb 2024, 03:06 PM IST
Next Story footLogo
Recommended For You
GENIE RECOMMENDS

Get the best recommendations on Stocks, Mutual Funds and more based on your Risk profile!

Let’s get started
Switch to the Mint app for fast and personalized news - Get App